Guest Editorial: Breast cancer in India: A continuing challenge

Indian Journal of Cancer

Volumn 47, Issue 1, 2010, Pages 1-2

  Gupta, Sudeep ^a  

^a TATA MEMORIAL HOSPITAL   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB;

ADJUVANT CHEMOTHERAPY; BREAST CANCER; CANCER INCIDENCE; CANCER RELAPSE; CANCER RISK; CANCER SURVIVAL; DRUG TARGETING; EDITORIAL; ERYTHROBLASTIC LEUKEMIA VIRAL ONCOGENE HOMOLOG 2; GENE OVEREXPRESSION; HEALTH CARE SYSTEM; HUMAN; INDIA; MASTECTOMY; ONCOGENE NEU; OVERALL SURVIVAL; PATIENT COMPLIANCE; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; PROTEIN TARGETING; TUMOR VOLUME; VIRUS ONCOGENE;

EID: 75749130707     PISSN: 0019509X     EISSN: 19984774     Source Type: Journal    
DOI: 10.4103/0019-509X.58849     Document Type: Editorial

References (9)

1. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-182
2. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2- overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999;17:2639-2648
3. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-792
4. Paik S, Bryant J, Tan-Chiu E, Romond E, Hiller W, Park K, et al. Real-world performance of HER2 testing-National Surgical Adjuvant Breast and Bowel Project experience. J Natl Cancer Inst 2002;94:852-854
5. Perez EA, Suman VJ, Davidson NE, Martino S, Kaufman PA, Lingle WL, et al. HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 Intergroup adjuvant trial. J Clin Oncol 2006;24:3032-3038
6. Vaidyanathan K, Kumar P, Reddy CO, Deshmane V, Somasundaram K, Mukherjee G. ErbB-2 expression and its association with other biological parameters of breast cancer among Indian women. Indian J Can 2010; 47:8-15.
7. Downs-Kelly E, Yoder BJ, Stoler M, Tubbs RR, Skacel M, Grogan T, et al. The infl uence of polysomy 17 on HER2 gene and protein expression in adenocarcinoma of the breast: A fl uorescent in situ hybridization, immunohistochemical, and isotopic mRNA in situ hybridization study. Am J Surg Pathol 2005;29:1221-1227
8. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, et al. American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer. J Clin Oncol 2007;25:118-145
9. Sandhu DS, Sandhu S, Karwasra RK, Marwah S. Profile of breast cancer patients at a tertiary care hospital in North India. Indian J Can 2010; 47:16-22.